Literature DB >> 1233249

Absorption, half-life, and toxicity of oral aprindine in patients with acute myocardial infarction.

F Hagemeijer.   

Abstract

Plasma concentrations of aprindine were used to assess its absorption, toxicity and disappearance rate after oral administration to patients within 24 hours of admission to a coronary care unit. Despite high oral doses, absorption was so slow that in half the patients effective plasma levels (exceeding 0.70 mug/ml) were not found during the first 12 hours of treatment. Therefore the oral route should not be used to treat cases of acute myocardial infarction with severe ventricular dysrhythmias. Clinical tolerance was good; there was one episode of delirium tremens in a chronic alcoholic (aprindine plasma concentration: 3 mug/ml); no case of tremor or cerebellar syndrome was observed. Disappearance of aprindine from plasma was slow, by far exceeding the half-lives found in healthy volunteers, and ranging from 20 to over 100 h. The variability of biological half-life in individual patients makes plasma level determiniations necessary whenever aprindine is to be administered for a long period.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233249     DOI: 10.1007/bf00613425

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Therapeutic effectiveness and plasma levels of aprindine, a new antidysrhythmic drug.

Authors:  J P Van Durme; M G Bogaert; M T Rosseel
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

2.  Effects of aprindine and lidocaine on transmembrane potentials and radioactive K efflux in different cardiac tissues.

Authors:  E Carmeliet; F Verdonck
Journal:  Acta Cardiol       Date:  1974       Impact factor: 1.718

3.  Pharmacological evaluation of aprindine (AC 1802) a new antiarrhythmic agent.

Authors:  A Georges; A Hosslet; G Duvernay
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

4.  Aprindine (AC 1802), a new anti-arrhythmic drug.

Authors:  H Kesteloot; W Van Mieghem; H De Geest
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

5.  Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Authors:  R G Talbot; J Nimmo; D G Julian; R A Clark; J M Neilson; L F Prescott
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

6.  Lignocaine given prophylactically to patients with acute myocardial infarction.

Authors:  A Pitt; H Lipp; S T Anderson
Journal:  Lancet       Date:  1971-03-27       Impact factor: 79.321

7.  Quinidine for prophylaxis of arrhythmias in acute myocardial infarction.

Authors:  S S Bloomfield; D W Romhilt; T C Chou; N O Fowler
Journal:  N Engl J Med       Date:  1971-10-28       Impact factor: 91.245

8.  Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.

Authors:  J Koch-Weser; S W Klein; L L Foo-Canto; J A Kastor; R W DeSanctis
Journal:  N Engl J Med       Date:  1969-12-04       Impact factor: 91.245

Review 9.  Comparative mechanisms of action of antiarrhythmic drugs.

Authors:  B N Singh; O Hauswirth
Journal:  Am Heart J       Date:  1974-03       Impact factor: 4.749

10.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

View more
  7 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  Disopyramide pharmacokinetics during recovery from myocardial infarction.

Authors:  S M Bryson; C J Cairns; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.

Authors:  P J Pentikäinen; M O Halinen; M J Helin
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Disopyramide pharmacokinetics in patients with acute myocardial infarction.

Authors:  P J Pentikäinen; H Huikuri; A J Jounela; G Wilen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.

Authors:  W McClennen; B Hornestam; U E Jonsson; P Held
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

7.  The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.

Authors:  L M Wing; P J Meffin; J J Grygiel; K J Smith; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.